Faculty & Speakers

John L. Marshall

The Evolution of Precision Medicine- Entering the Era of Multi-omics

Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital

Director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Washington DC, USA

David S.Hong

Cracking open the undruggable RAS: A Clinical Perspective

Associate Vice President of Clinical Research, University of Texas M.D. Anderson Cancer Center

Deputy Chair of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, Houston, USA.

Zoran Gatalica

Apocrine breast carcinoma from biomarkers to therapy

Director of Anatomic Pathology, University of Oklahoma Health Sciences Center, Oklahoma, USA. 

Disis, Mary L. (Nora)

Solid Tumors: Immuno-Oncology

Director, Cancer Vaccine Institute, University of Washington (UW)

Director, Institute of Translational Health Sciences UW, Seattle, WA, USA

Che-Kai Tsao

Age of combination therapy in the treatment of advanced RCC: can we do it better?

Medical Director, Ruttenberg Treatment Center, Tisch Cancer Institute, Mount Sinai Hospital, NY, USA.

Eugene V Koonin

Mutation-Selection Balance and Compensatory Mechanisms in Tumor Evolution

National Center for Biotechnology Information, National Library of Medicine,

National Institutes of Health,  Bethesda, MD, USA

Astero Klampatsa

Overcoming Tumor Antigen Heterogeneity in the Context of CAR T Cell therapy for Solid Tumors

Thoracic Oncology Immunotherapy Group, The Institute of Cancer Research, Division of Cancer Therapeutics, London, UK

Panos Z. Anastasiadis

Combination of integrated genomics with ex vivo microcancer drug screens to individualize brain cancer therapy

Cell Biology Program Director, Cell Adhesion and Metastasis Laboratory

Mayo Clinic Cancer Center,  Jacksonville, FL, USA

Pedro Barata

Patient selection for PARP Inhibitors: Genomic Considerations

Tulane Medical School Department of Internal Medicine, Section of Hematology and Medical Oncology, New Orleans, Louisiana,USA.

Leena Latonen

Potential prostate cancer targeting strategies revealed by integrative proteogenomics

School of Medicine, Institute of Biomedicine, University of Eastern Finland

Kuopio, Finland

Jorge A. Garcia

Importance of Genomics in Prostate Cancer: Role of PARPi in CRPC

Division Chief, Solid Tumor Oncology University Hospitals Seidman Cancer Center

Cleveland, OH, USA

Francisco La Rosa

The Third Dimension in Prostate Cancer

University of Colorado, AMC Department of Pathology, Aurora, CO, US

Sanja Aveic

The Role of LIN28B Oncogene in Regulating Migration & Invasion of Neuroblastoma Cells

Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Padua, Italy

RWTH Aachen University Hospital, Dental Materials and Biomaterials Research, Aachen, Germany

Ehab Atallah

TKIs in Chronic Myelogenous Leukemia (CML) Therapy: Monitoring & Mechanisms of resistance

Section Head, hematological malignancies, Medical College of Wisconsin, Milwaukee, WI, USA

Armando Bartolazzi

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs

Department of Pathology, Sant’Andrea University Hospital, Rome, Italy

Cara Haymaker

Identification of distinct immune signatures in malignant pleural mesothelioma

Director, Oncology Research and Immuno-monitoring Core (ORION)

Director, Translational Molecular Pathology and Immunoprofiling Lab,

UT MD Anderson Cancer Center, Houston, TX, US

Dario Longo

Imaging of tumor acidosis for monitoring response to novel anticancer therapies

Institute of Biostructures and Bioimaging (IBB), Italian National Research Council (CNR)

Torino, Italy

Kendra Sweet

Outcome of patients receiving 2nd line or later CML Therapy

Department of Malignant Hematology H. Lee Moffitt Cancer Center Tampa, FL, USA

Jianyu Rao

Molecular Testing and Liquid Biopsy for Ovarian Cancer

UCLA Medical Center, Santa Monica, LA, USA

Antonio Facchiano

Investigating protein- and gene-expression of 27 cytokines/chemokines in melanoma patients. Identification of a 4-genes signature

Istituto Dermopatico dell’Immacolata (IDI-IRCCS), Rome, Italy

Shilpa Gupta

Second-line Therapy & Beyond in Metastatic Urothelial Carcinoma

Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio

Yufang Shi

Mesenchymal stem/stromal cells and the tumor tissue microenvironment

Soochow University Institutes for Translational Medicine &

Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China

Cristina M. Failla

Vitiligo and vitiligo-associated markers as indicators of response to immunological checkpoint inhibitors in cutaneous melanoma

Experimental Immunology Laboratory, IDI-IRCCS, Rome, Italy

Jonathan A. Kelber

Modeling Therapy-Induced Tumor Cell State Plasticity to Identify Vulnerabilities for Reducing Disease Burden

Department of Biology, California State University Northridge (CSUN)

Los Angeles, California

Licia Iacoviello

The common soil hypothesis for Cancer and Cardiovascular disease: evidence from experimental and epidemiological studies

IRCCS Neuromed, Pozzilli & University of Insubria Varese, Italy

Julie Goodwin

Glucocorticoids and Angiogenesis

Yale School of Medicine, New Haven, CT, USA

Bruna Corradetti

Advanced ovarian cancer: exploiting exosomes to potentiate the anti-cancer immune response

Houston Methodist Research Institute, Houston, USA

School of Medicine at Swansea University, Wales, UK

Michael Levin

Ion channel drugs as electroceuticals for reprogramming cancer: exploiting bioelectric controls of cell and tissue function

Director, Allen Discovery Center at Tufts and Tufts Center for Regenerative and Developmental Biology, Tufts University, Medford, USA.

Y-h. Taguchi

Tensor-Decomposition-Based Unsupervised Feature Extraction Applied to Prostate Cancer Multiomics Data

Department of Physics, Chuo University, Tokyo, Japan

Mads Daugaard

Targeting glycosaminoglycans in solid tumors

Molecular Pathology & Cell Imaging Core Facility, Vancouver Prostate Centre

Department of Urologic Sciences, University of British Columbia, Vancouver, Canada

Andreas Pircher

Tumor Endothelial Cells in NSCLC: headmasters of tumor immunity

Department of Internal Medicine V (Hematology and Oncology)

Medizinische Universität Innsbruck, Innsbruck, Austria

Qian Xie

MET as a druggable target in solid tumors

Department of BioMedical Sciences, Quillen College of Medicine, East Tennessee State University, Johnson City, US

Pier Giorgio Natali

The role of General Practitioners in Cancer Control. An underexploited resource in translational oncology

Ex. Scientific Director, Regina Elena Institute (IRE), Rome, Italy.

Moonsoo M. Jin

A phase I study of Affinity-tuned ICAM-1 specific CAR T against advanced thyroid cancer patients

Director, Molecular Imaging Innovations Institute (MI3), Department of Radiology, Weill Cornell Medicine, New York, USA

Marzia Del Re

Unleashing the potential of liquid biopsy in solid tumors: diagnosis, recurrence and resistance

Unit of Clinical Pharmacology and Pharmacogenetics, Dipartimento di Medicina Clinica e Sperimentale, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy

Elisabeth Heath

Prostate Cancer PARP Combination Clinical Trials

Karmanos Cancer Institute, Wayne State School of Medicine, Detroit, Michigan

Gerry Melino

The Role of p63 in the Female Germline Fidelity and Related Cancers

Director of Department & Professor of Molecular Biology, Faculty of Medicine, University of Rome – Tor Vergata, Rome, Italy.

Silvia De Francia

Two retrospective studies on gender differences: chemotherapy toxicities in patients affected by colorectal and pancreatic cancers

 Department of Clinical and Biological Sciences, University of Turin, Orbassano (TO), Italy

Vadim Koshkin

Ongoing Clinical Trials in Advanced Urothelial Carcinoma & Future Directions

Division of Hematology and Oncology, University of California San Francisco, US

Giuseppe Saglio

Do we need new TKIs for CML therapy?

Division of Internal Medicine and Haematology, University of Turin, Turin, Italy

Francesca Granucci

Role of calcineurin in affecting tumor growth and the formation of the tumor microenvironment

Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy

Leana Rich M. Herrera

Designing a Multi-Epitope Vaccine Against Cancer-Testis Antigens in Non-Small Cell Lung Cancer: an In Silico Approach (Poster Talk)

Polytechnic University of the Philippines, Philippines.

Ye-Lin Liang

A lncRNA signature associated with tumour immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinoma (Poster Talk)

Sun Yat-sen University Cancer center, Guangzhou, China